Chief Financial Officer
CurrentARS Pharmaceuticals is developing an intranasal epinephrine product for patients with type 1 severe allergic reactions. Kathy was deeply involved in a reverse merger with Silverback Therapeutics and is preparing for a commercial launch upon FDA approval anticipated in 2024.